Imatinib-induced Psoriasiform Drug Eruption in a Patient with a Gastrointestinal Stromal Tumor.
- Author:
Ye Jin LEE
1
;
Woo Jin LEE
;
Sungeun CHANG
;
Mi Woo LEE
;
Jee Ho CHOI
;
Kee Chan MOON
Author Information
1. Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. miumiu@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Gastrointestinal stromal tumor;
Gleevec;
Imatinib mesylate;
Psoriasis
- MeSH:
Aged;
Drug Eruptions*;
Edema;
Exanthema;
Extremities;
Gastrointestinal Stromal Tumors*;
Humans;
Male;
Mesylates;
Oncogene Proteins;
Protein-Tyrosine Kinases;
Pruritus;
Psoriasis;
Imatinib Mesylate
- From:Korean Journal of Dermatology
2015;53(5):388-391
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imatinib mesylate (Gleevec(R)) is a small-molecule inhibitor that selectively inhibits the tyrosine kinase family, including mutated KIT oncoproteins in gastrointestinal stromal tumors (GIST). However, cutaneous reactions to imatinib are common and occur in 7.0% to 88.9% of patients. Nonspecific skin rashes, facial edema, and pruritus are the most common adverse reactions. However, development of psoriasiform drug eruption owing to the drug has rarely been reported. Herein we report on a 66-year-old male patient with GIST who had taken imatinib (400 mg/day) for 2 months. He developed erythematous scaly macules and papules on the trunk and extremities. Histopathological findings were compatible with a psoriasiform drug eruption.
